Pediatric Priorities: Legislative and Regulatory Initiatives to Expand Research on the Use of Medicines in Pediatric Patients by Labson, Michael S.
Journal of Health Care Law and Policy
Volume 6 | Issue 1 Article 4
Pediatric Priorities: Legislative and Regulatory
Initiatives to Expand Research on the Use of
Medicines in Pediatric Patients
Michael S. Labson
Follow this and additional works at: http://digitalcommons.law.umaryland.edu/jhclp
Part of the Bioethics and Medical Ethics Commons, and the Health Law Commons
This Article is brought to you for free and open access by DigitalCommons@UM Carey Law. It has been accepted for inclusion in Journal of Health
Care Law and Policy by an authorized administrator of DigitalCommons@UM Carey Law. For more information, please contact
smccarty@law.umaryland.edu.
Recommended Citation
Michael S. Labson, Pediatric Priorities: Legislative and Regulatory Initiatives to Expand Research on the Use of Medicines in Pediatric
Patients, 6 J. Health Care L. & Pol'y 34 (2002).
Available at: http://digitalcommons.law.umaryland.edu/jhclp/vol6/iss1/4
PEDIATRIC PRIORITIES: LEGISLATIVE AND REGULATORY
INITIATIVES TO EXPAND RESEARCH ON THE USE OF
MEDICINES IN PEDIATRIC PATIENTS
MICHAEL S. LABSON, J.D.*
I. INTRODUCTION
The evolution of prescription drug regulation in the United States has been
inextricably tied to pediatric health issues. In the fall of 1901, thirteen children
died of tetanus in St. Louis after being treated with a diphtheria antitoxin made
from the blood of an infected milk wagon horse.' Less than a year later, Congress
enacted the Biologics Control Act of 1902,2 which remains the cornerstone of the
federal regulation of biologics.3 In 1937, scores of children died after taking Elixir
of Sulfanilamide, a new "wonder drug" for the treatment of infections that
contained the solvent diethylene glycol (better known today as antifreeze).4
Congress subsequently enacted the landmark Food, Drug, and Cosmetic Act of
19385 (FDCA) to provide the Food and Drug Administration (FDA) with new
authority to require that drugs be demonstrated to be safe before they may be
introduced into interstate commerce.6 In the late 1950s and early 1960s, some
10,000 children worldwide were born with birth defects to women who had taken
the sedative thalidomide during their pregnancy. 7  Spurred in large part by the
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1. Ramunas A. Kondratas, Biologics Control Act of 1902, in THE EARLY YEARS OF FEDERAL
FOOD AND DRUG CONTROL 8, 14-15 (Glenn Sonnedecker ed., 1982).
2. Pub. L. No. 244, 32 Stat. 728 (1902).
3. PETER BARTON HUTT & RICHARD A. MERRILL, FOOD AND DRUG LAW 661 (2d ed. 1991).
4. Charles Wesley Dunn, Report of the Secretary of Agriculture on Deaths Due to Elixir
Sulfanilamide--Massengill, in FEDERAL FOOD, DRUG, AND COSMETIC ACT: A STATEMENT OF ITS
LEGISLATIVE RECORD 1316-27 (G.E. Stechert & Co. ed., 1938).
5. Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended 21 U.S.C.S. §§ 301 et seq.
(LEXIS 1997 & Supp. 2002)).
6. M.L. Yakowitz, The Evolution of the Drug Laws of the United States, 1906-1964, 19 FOOD
DRUG COSMETIC L. J. 296, 297-98 (1964); David F. Cavers, The Food, Drug, and Cosmetic Act of
1938: Its Legislative History and Its Substantive Provisions, 6 LAW & CONTEMP. PROBS. 2, 20 (1939).
7. MORTON MINTz, THE THERAPEUTIC NIGHTMARE 248-64 (1965); RICHARD HARRIS, THE
REAL VOICE 184-90 (1964). Although thalidomide was never approved in the United States, some
women were still able to obtain it. HARVEY TEFF AND COLIN MUNRO, THALIDOMIDE: THE LEGAL
AFTERMATH 4-7 (1979). Many of the affected babies were born in Europe, where thalidomide was
available commercially. Id.
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tragedy, Congress enacted the Drug Amendments of 19628 to require that all new
drugs be proven not only safe but also effective before coming onto the market.9
Pediatric health crises have thus prompted fundamental changes to the laws
that govern the review and approval of human drugs in the United States. While
these events have led to overarching reforms in the drug approval process,
however, children themselves have often been left behind. Years ago, Dr. Harry
Shirkey labeled children "therapeutic orphans" because the medicines being used
to treat children had not been adequately studied and labeled for use in pediatric
patients.1l Dr. Shirkey's pronouncement has been echoed often over the years.
One survey based on data from 1991 to 1994 indicated that 71 per cent of all new
molecular entities lacked labeling information on pediatric use."' The Congress
similarly concluded in 1997: "When it comes to pharmaceuticals, our Nation's
children are 'therapeutic orphans."'
12
Without information on pediatric use for a particular drug, physicians can be
left in the difficult position of having either to prescribe a drug without knowing its
precise effects in children, or to use a potentially inferior alternate treatment for
which pediatric information is available. 13 Both the safety and efficacy of therapy
can suffer as a result. The need for securing the study and labeling of more
medicines for pediatric use is thus clear. Unfortunately, however, so are the
obstacles.
There are comparatively small numbers of pediatric patients with any
particular disease in most cases. 14 As a result, there are fewer patients available to
recruit for clinical trials, and a smaller commercial market in which the medication
can be used.' 5 Where patient numbers are adequate, it can still be difficult to find
patients (and parents) who are willing to participate in research. 16 Additionally,
conducting research in children can raise heightened legal and ethical
considerations surrounding matters such as informed consent, and the risk of
liability can be greater. 17 Where these concerns can be overcome, there may be
technical difficulties in conducting research with children. For example, it may be
8. Pub. L. No. 87-781, 76 Stat. 780 (1962).
9. Drug Efficacy and the 1962 Drug Amendments, 60 GEO. L.J. 185, 191 n.45 (1971); Teff &
Munro, supra note 7, at 121-24.
10. Harry Shirkey, Editorial Comment: Therapeutic Orphans, 72 PEDIATRICS 119, 119 (1968).
11. See John T. Wilson, An Update on the Therapeutic Orphan, 104 PEDIATRICS 585, 586 (at
Table 2) (1999).
12. S. REP. No. 105-43, at 51 (1997).
13. See generally Committee on Drugs, American Academy of Pediatrics, Guidelines for the
Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations, 95 PEDIATRICS 286 (1995).
14. Ralph E. Kauffman, Therapeutic Challenges: Prenatal and Paediatric Safety Considerations,
5 DRUG SAFETY 65, 69 (1990).
15. Id.
16. Benedetto Vitiello, MD & Peter S. Jensen, MD, Medication Development and Testing in
Children and Adolescents, 54 ARCH. GEN. PSYCHIATRY 871, 873 (1997).
17. See, e.g., Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807 (Md. App. 2001).
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difficult to develop a drug formulation for use with younger age groups (e.g., a
liquid for infants). 18 Or it may be more difficult to measure the outcomes of
certain kinds of treatments in the pediatric population, including, for example,
treatments like anti-depressants that may require self-evaluation by patients to
determine effectiveness.' 9
The net effect of all these factors is that the incentives to conduct pediatric
research can be small and the disincentives significant, particularly when
pharmaceutical research companies are considering how to allocate their scarce
research dollars among competing projects. As Congress concluded in 1997:
[T]here is little incentive for drug sponsors to perform studies for medications
which they intend to market primarily for adults and whose use in children is
expected to generate little additional revenue. Pediatric studies pose ethical
and moral issues relating to using new unapproved drugs in young patients.
Second, there are substantial product liability and medical malpractice issues.
Third, pediatric patients are more difficult to attract into studies. Fourth, for
some drugs, pediatric use represents more difficult issues of drug
administration and patient compliance than adult use.2 °
It is therefore, perhaps, not that surprising that the challenge of meeting Dr.
Shirkey's call for more pediatric research has persisted for so long. Real progress
requires an approach that addresses the seemingly intractable root causes that
underlie the problem in the first instance.
Well, help has finally arrived due in large part to innovative new federal
initiatives that have been pursued in the past five years. These initiatives have
brought unprecedented progress precisely because they address the systemic
obstacles that have previously inhibited pediatric research. At the center of the
federal government's current pediatric initiative are new incentives for drug
sponsors to conduct pediatric studies. These incentives were established by the
Better Pharmaceuticals for Children Act, which was enacted as part of the FDA
Modernization Act of 1997 (FDAMA).2' The incentives have been complemented
by pediatric study requirements that FDA has imposed through regulation under
the so-called Pediatric Rule.22 FDA's authority to mandate studies in this way is
18. See BERT SPILKER, GUIDE TO CLINICAL TRIALS 132 (1991) (discussing potential problems
associated with dosage forms such as solutions and suspensions typically used for children).
19. Vitiello & Jensen, supra note 16, at 873 (discussing the difficulties that can arise in detecting
drug effects in children).
20. S. REP. No. 105-43, at 51 (1997).
21. Pub. L. No. 105-115, 111 Stat. 2296 (1997), available at
http://www.fda.gov/opacom/7modact.htm (last visited Dec. 19, 2002).
22. Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs
and Biological Products in Pediatric Patients, 63 Fed. Reg. 66,632 (Dec. 2, 1998).
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controversial, and was in fact invalidated in a recent federal court decision holding
that FDA exceeded its statutory authority in promulgating the Pediatric Rule.23
Even before this ruling, however, the agency had allowed the incentives to work
first in practice, and only used the Pediatric Rule as a default to ensure that needed
studies are completed.24
The pediatric incentives from FDAMA and the requirements from the
Pediatric Rule had worked together like the proverbial carrot and stick to ensure
that drugs are studied and labeled for pediatric use. These laws were and are
further complemented, in turn, by the final piece of the current federal pediatric
initiative, the Best Pharmaceuticals for Children Act (BPCA). 25 The BPCA was
enacted at the beginning of 2002 and addresses gaps in the pediatric incentive
provisions of FDAMA by establishing new public programs through the National
Institutes of Health (NIH) to fund studies on off-patent and certain other drugs.
The BPCA also reauthorized the incentives that had been created in FDAMA, and
modified certain other aspects of the incentive provisions.
This article discusses these three legislative and regulatory enactments in
detail to understand the differing provisions in each, as well as how they have
worked together to promote pediatric research and labeling. Section one provides
some historical context by summarizing prior FDA pediatric initiatives tracing
back to the 1970s. Section two explains how the incentives from FDAMA work,
and why (after surviving an early legal challenge by generic drug manufacturers)
the incentives have been so successful. Section three reviews the study
requirements of the Pediatric Rule, how they related to the FDAMA incentives, the
recent court decision holding the Rule invalid, and legislative proposals to revive
the Rule. Finally, section four covers the BPCA, including the new NIH study
programs established by the legislation and the modifications that were made to the
FDAMA incentive provisions.
In reviewing FDAMA, the Pediatric Rule, and the BPCA, it is striking how
much attention the federal government has paid in the past five years to
encouraging pediatric research and pediatric drug labeling. While children may
have been left behind during earlier reforms of the country's drug approval laws, it
is clearly now a top public health priority for both the executive and legislative
branches to find specific solutions to pediatric health needs.
23. See Ass'n of Am. Physicians and Surgeons, Inc., et al., v. U.S. FDA, et al., No. CIVA.00-
02898, 2002 WL 31323411, *6 (D.D.C. Oct. 17, 2002).
24. See, e.g., 63 Fed. Reg. at 66,654 ("[B]efore imposing any requirements under [the Pediatric
Rule], FDA intends to allow manufacturers eligible for FDAMA incentives an adequate opportunity to
voluntarily conduct studies of marketed drugs in response to those [FDAMA] incentives. If, following
such an opportunity, there remain marketed drugs for which studies are needed and the compelling
circumstances described in the rule are met, the agency will consider exercising its authority to require
studies.").
25. Pub. L. No. 107-109, 115 Stat. 1408 (2002).
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All indications are that these efforts are producing demonstrable results.
Although it may be premature to provide a final report card on the initiatives, at
least two basic lessons have emerged. First, it seems clear that government
intervention was needed. The obstacles to pediatric research that are otherwise
present have simply been too difficult to overcome without legal and regulatory
action. Second, the most effective government intervention has proven to be the
adoption of meaningful incentives that encourage voluntary industry action. This
is not to say that there has been no role for regulatory mandates or publicly-funded
programs. But the experience thus far demonstrates that the incentives created by
FDAMA, and reauthorized in the BPCA, most directly address the underlying
causes for the lack of pediatric research.
As FDA itself concluded, the incentives have "done more to generate clinical
studies and useful prescribing information for the pediatric population than any
other regulatory or legislative process to date. 26  At least on this issue, then,
government-generated incentives have proven most effective, while the more
traditional approaches of establishing regulatory mandates and providing public
funding operate to address gaps and provide a safety net where the voluntary
incentives have not worked.
II. PRIOR PEDIATRIC INITIATIVES
FDA has appreciated the need to study medicines for pediatric use for some
time. It may be necessary to develop and validate new formulations that younger
patients can take. Where the formulations exist, without appropriate clinical
testing there may not be a sound scientific basis for knowing whether a medicine is
safe and effective for children, or for knowing what dosing should be used for
different pediatric populations.27 Where adult data exist, the data may or may not
be extrapolated to children. Children are not "miniature adults," 28 and differences
in metabolism and physiology can influence how drugs work in different age
patients.
Younger patients may require lower dosing because their reduced ability to
clear drugs from the body creates a risk of toxicity. 29 Alternatively, some drugs
can be cleared more rapidly by the immature systems in younger patients, and
26. U.S. FDA, Dep't of Health and Hum. Servs., The Pediatric Exclusivity Provision: January
2001 Report to Congress at ii (2001) available at http://www.fda.gov/cder/pediatric/reportcong0l.pdf
(last visited Oct. 8, 2002) (soliciting comments for report) [hereinafter FDA Report to Congress]; see
also Report to Congress on Pediatric Exclusivity; Requests for Comments, 65 Fed. Reg. 26,217 (May 5,
2000).
27. Kauffman, supra note 14, at 68; John T. Wilson et al., Paediatric Labelling Requirements:
Implications for Pharmacokinetic Studies, 26 CLIN. PHARMACOKINET. 308, 310 (1994).
28. William R. Crom, Pharmacokinetics in the Child, 102 ENVTL. HEALTH PERSP. Il l, Ill
(1994).
29. Kauffman, supra note 14, at 68.
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higher dosing may be needed to ensure that enough drug is absorbed to be
effective. 30 It may therefore often be necessary to conduct clinical trials to ensure
that an adequate scientific basis exists for use of a drug in pediatric patients.
Additionally, it is important to capture the available data in FDA-approved drug
labeling. This official labeling does not necessarily contain the latest available
scientific and clinical information on use of a drug, and physicians remain free to
prescribe a drug outside of the FDA labeling.31 Nevertheless, the labeling provides
pediatricians and other physicians at least one widely available and authoritative
32source for guidance.
For these reasons, FDA has made various attempts over the years to prompt
drug manufacturers to conduct pediatric studies and submit proposed pediatric
labeling. The most significant agency actions in this regard prior to those of the
past five years occurred in 1979 and in 1994. These administrative measures,
combined with other related agency actions, provide the historical backdrop
leading up to the enactment of the FDAMA pediatric provisions in 1997 and final
promulgation of the Pediatric Rule in 1998.
A. FDA's 1979 Prescription Labeling Rewrite
FDA has struggled perennially with how to improve the format and content
of the agency-approved labeling for human prescription drugs (also known as the
package insert or full prescribing information), so that the labeling will be useful
and informative for prescribers. 33  The labeling contains detailed information
approved by FDA on a drug's properties and official conditions for use, including
sections on clinical pharmacology, indications and usage, contraindications,
warnings, precautions, adverse reactions, dosage and administration, etc. 34 One
major attempt to enhance prescription drug labeling came in the 1970s. FDA
proposed the new rules in 197535 and promulgated final regulations in 1979.36 In
addition to making general improvements to prescription drug labeling, these new
regulations sought specifically to address the need for greater information on the
use of drugs in pediatric patients.
30. Id.
31. David A. Kessler, Regulating the Prescribing of Human Drugs for Nonapproved Uses Under
the Food, Drug, and Cosmetic Act, 15 HARV. J. ON LEGIS. 693, 723 (1978).
32. Wilson, supra note 11, at 585.
33. See, e.g., Requirements on Content and Format of Labeling for Human Prescription Drugs and
Biologics; Requirements for Prescription Drug Product Labels, 65 Fed. Reg. 81,082 (Dec. 22, 2000)
(setting forth FDA's most recent proposed rewrite of the requirements for prescription drug labeling).
34. Specific Requirements on Content and Format of Labeling for Human Prescription Drugs, 21
C.F.R. § 201.57 (2002).
35. Labeling for Prescription Drugs Used in Man, Proposed Format for Prescription Drug
Advertisements, 40 Fed. Reg. 15,392 (Apr. 7, 1975).
36. Labeling and Prescription Drug Advertising; Content and Format for Labeling for Human
Prescription Drugs, 44 Fed. Reg. 37,434 (June 26, 1979).
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Under the rule, all prescription drugs were required to include a pediatric use
subsection within the precautions section of the labeling.37 The rule required that
if the drug is approved for a pediatric indication, that indication must be described
under the indications and usage section of the labeling, with dosing information
provided under the dosage and administration section.3 If there is no approved
pediatric use, the labeling must state that "[s]afety and effectiveness in children
have not been established" or that "[s]afety and effectiveness in children below the
age of [ ] have not been established., 39 Such statements have appeared in drug
labeling ever since.
The limitations of the 1979 rule are obvious. The labeling requirements
"inform physicians if data are unavailable concerning the safe and effective use of
a drug in pediatric patients. '4° However, the requirements did nothing to develop
additional information on whether or how to use a drug in children. As FDA
explained, the rule "neither requires nor is intended to require that studies be
performed to develop data for inclusion in prescription drug labeling.
'Al
III. FDA'S 1994 PEDIATRIC LABELING RULE
In 1994, FDA went a step further. Due to growing agency concerns about the
lack of pediatric information in existing prescription drug labeling, FDA proposed
in 1992,42 and then finalized in 1994, 43 a requirement that all sponsors of drug and
biologics products examine available data on pediatric use and submit a
supplemental application for a pediatric indication if supported by the existing
data.4  At the same time, FDA clarified that its standards for approving new
pediatric uses are flexible, and can permit expanded pediatric labeling based on
available adult data and supporting pediatric information.
FDA explained that it can be difficult to conduct controlled clinical trials with
pediatric patients because of "the many problems associated with the testing of
drugs in the pediatric population (e.g., obtaining informed consent for tests not
directly of benefit to the child, use of placebo controls in a vulnerable
37. 44 Fed. Reg. at 37,465 (codified as 21 C.F.R. § 201.57(f)(9) (2002)). This basic requirement
remains in place today, as amended.
38. 21 C.F.R. § 201.57(f)(9) (2002).
39. Id.
40. 44 Fed. Reg. at 37,453.
41. Id.
42. Specific Requirements on Content and Format of Labeling for Human Prescription Drugs;
Proposed Revision of "Pediatric Use" Subsection in the Labeling, 57 Fed. Reg. 47,423 (Oct. 16, 1992).
43. Specific Requirements on Content and Format of Labeling for Human Prescription Drugs;
Revision of "Pediatric Use" Subsection in the Labeling, 59 Fed. Reg. 64,240 (Dec. 13, 1994).
44. Id. at 64,248 ("Sponsors must, therefore, reexamine existing data to determine whether the
"Pediatric use" subsection of the labeling can be modified . and, if appropriate, submit a
supplemental application .... ).
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population)945 FDA emphasized that the law provides flexibility, though, where
other evidence is available of a drug's effectiveness in a population:
A pediatric use statement may also be based on adequate and well-controlled
studies in adults, provided that the agency concludes that the course of the disease
and the drug's effects are sufficiently similar in the pediatric and adult populations
to permit extrapolation from the adult efficacy data to pediatric patients. Where
needed, pharmacokinetic data to allow determination of an appropriate pediatric
dosage, and additional pediatric safety information must also be submitted.46
The 1994 regulation thus sought to encourage pediatric labeling both by
making clear the different criteria that may be used to obtain pediatric approval,
and by directing drug and biologic sponsors to determine whether available data
47could support pediatric use.
The 1994 rule is significant in several regards. First, it constitutes an explicit
acknowledgement by FDA of the difficulties of conducting classic placebo-
controlled trials in pediatric patients, and the resulting need in at least some cases
to extrapolate from adult data with limited supporting pediatric data. Second, the
rule broke new ground by imposing an affirmative requirement on drug sponsors to
submit supplemental applications if supported by available data. In imposing this
requirement, the rule was limited in scope. FDA made clear that a sponsor need
not seek pediatric labeling if the sponsor determined that the data were inadequate
to establish that the benefits of pediatric use outweighed the risks.48
Although the agency maintained its legal authority to compel new pediatric
studies, 49 the agency emphasized that the 1994 rule "does not add a new
requirement that sponsors carry out new pediatric studies, nor does it require that
sponsors submit labeling with claims that are inadequately supported. ' '50 In cases
where the sponsor determined that the existing data did not support pediatric use,
labeling could simply state, as before, that "safety and effectiveness in pediatric
patients below the age of [ ] have not been established. ' 51
45. Id. at 64,240.
46. Id. at 64,241.
47. Id. The 1994 rule also required that more comprehensive information be included on pediatric
use in the different sections of the labeling, including, for example, in the sections on indications and
usage, dosage and administration, clinical pharmacology, clinical studies, contraindications, and
warnings. Id.
48. Id. at 64,243.
49. Id. ("[V]arious provisions of the Federal Food, Drug, and Cosmetic Act (the Act), the Public
Health Service Act (the PHS Act), and existing regulations authorize FDA to require [pediatric] studies
under certain circumstances.").
50. Id. at 64,242.
51. Id. at 64,241.
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IV. RELATED AGENCY ACTIONS
FDA followed publication of the 1994 pediatric rule with various less formal
agency attempts to expand the development of pediatric labeling. For example, the
groups within FDA responsible for the review and approval of new drugs and
biologics (the Center for Drug Evaluation and Research and the Center for
Biologics Evaluation and Research) adopted a "Pediatric Plan" intended to raise
pediatric issues with sponsors during the drug research and development process
and encourage pediatric studies. 52 In addition, FDA reviewers began completing a
"pediatric page" for each new drug or biologics application, which stated whether
the product was labeled for pediatric use, and whether additional pediatric studies
were needed and planned.53 Both of these agency initiatives were aimed solely at
prompting voluntary actions on the part of sponsors to undertake additional
pediatric research.
A. Results from FDA Actions
The effectiveness of the 1994 rule and the FDA's related pediatric initiatives
was mixed, and somewhat disputed. In public comments submitted to FDA in
November 1997, the Pharmaceutical Research and Manufacturers of America
(PhRMA) (a trade association representing research-based pharmaceutical and
biotechnology companies) reported that 75 companies were then developing 146
new drugs that had been or would be studied in children.54 According to the
PhRMA comments, 19 of the 20 new drugs that were approved in the prior year,
and that had potential for pediatric use, also had been or would be studied in
children.55 In addition, PhRMA cited reports that drug sponsors had responded to
the 1994 pediatric rule by submitting some 200 supplemental applications to
FDA.56
FDA took a different view. In August 1997, the agency acknowledged that
its initiatives had "produced some gains in pediatric labeling." 57 However, the
agency ultimately concluded that its prior actions "have not yet substantially
increased the number of drugs and biological products for which there is adequate
pediatric use information. 58 FDA thus prepared to take further action. Congress
also decided to enter the mix, thereby ushering in the current phase of federal
initiatives to broaden pediatric drug labeling.
52. See Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New
Drugs and Biological Products in Pediatric Patients, 62 Fed. Reg. 43,900, 43,901 (Aug. 15, 1997).
53. See id. at 43,901-02; see also Wilson et al., supra note 27, at 314.
54. Comments of the PhRMA Submitted to the Dockets Management Branch of the FDA on
Docket No. 97N-0165, at 2 (Nov. 13, 1997) (on file with the Journal of Health Care Law & Policy).
55. Id.
56. Id. at 3.
57. 62 Fed. Reg. at 43,902.
58. Id.
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B. The Current Pediatric Initiative Part 1: The Carrot of Pediatric Exclusivity
As a matter of chronology, the next milestone in our unfolding pediatric story
was FDA's determination in 1997 to propose a regulation that would compel
manufacturers of certain drugs to conduct pediatric studies, the so-called Pediatric
Rule.5 9 Before the Pediatric Rule was finalized, however, Congress intervened and
adopted a quite different approach as part of the FDA Modernization Act of 1997.
V. THE FDA MODERNIZATION ACT OF 1997 (FDAMA)
The FDA Modernization Act of 1997 (FDAMA) 60 was a broad reform statute
with provisions addressing a wide range of issues under FDA's regulatory
umbrella. Section 111 of FDAMA established a new detailed statutory program to
enhance the incentives for the sponsor of a new drug application (NDA) to conduct
pediatric studies and collect pediatric use information at FDA's request on new and
already approved drugs.
These pediatric incentive provisions are codified at section 505A of the
Federal Food, Drug, and Cosmetic Act (FDCA).6' Companies that satisfy the
requirements of section 505A earn six months of additional marketing
"exclusivity" for a drug. The six months of exclusivity effectively extend existing
patent and other exclusivity protections by lengthening by six months the period
during which FDA cannot approve a generic copy of an innovator drug based on
an abbreviated NDA that relies on the safety and effectiveness data in the
innovator's full NDA.62
Under the new statute, the procedures for obtaining pediatric exclusivity for a
drug that is already approved are as follows:
A. Pediatric List
FDA was required to develop, prioritize, and publish annually a list of
"approved drugs for which additional pediatric information may produce health
59. Id.
60. Pub. L. No. 105-115, 111 Stat. 2296 (1997).
61. See 21 U.S.C.S. § 355a (LEXIS 1997 & Supp. 2002) (FDCA § 505A). As noted below, the
provisions have been amended somewhat, and renumbered, by the Best Pharmaceuticals for Children
Act (BPCA). For reference, citations are provided to both the original and renumbered provisions of
the FDCA, and an explanation of significant amendments to the provisions is noted.
62. See id. at §§ 355a(b) & (c) (FDCA § 505A(b) & (c)), formerly 21 U.S.C. §§ 355a(a) & (c)
(FDCA §§ 505A(a) & (c)). Orphan drug exclusivity is also extended by six months, which prevents
approval of both generic and branded versions of drugs that enjoy orphan drug exclusivity under 21
U.S.C. § 360cc(a) (FDCA § 527(a)). The generic copies of innovator drugs may be approved based on
the safety and effectiveness data submitted for the innovator drug. See id. §§ 355(b)(2) & (J) (FDCA
§§ 505(b)(2) and (j)). However, generic approvals are subject to the patent and other exclusivity rights
that apply to the innovator drug that the generic is copying. Id.; see also Mova Pharm. Corp. v. Shalala,
140 F.3d 1060, 1063 (D.C. Cir. 1998) (explaining the generic drug approval process).
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benefits in the pediatric population. 63 Marketed drugs had to be on this list to
receive a written request for pediatric studies.
B. Written Request
Next, FDA makes a "written request" for pediatric studies to the holder of an
approved NDA for a drug included on the pediatric list.64 The written request must
include a timeframe for completing the studies. 65 "Pediatric studies" are defined
under the law as "at least one clinical investigation (that, at the Secretary's
discretion, may include pharmacokinetic studies) in pediatric age groups in which
a drug is anticipated to be used." 66 Qualifying studies can therefore range from
smaller pharmacokinetic studies to broader studies evaluating safety or
effectiveness.
C. NDA Holder Agrees to the Request
The pediatric exclusivity provisions are intended to be voluntary.
Accordingly, drug sponsors remain free to respond to a written request or not to
respond.67
D. Agreement on Study Design (Protocols)
Studies may be conducted in response to a written request pursuant to an
agreement with FDA on study protocols or, in the absence of such an agreement,
"in accordance with commonly accepted scientific principles and protocols.,
68
E. Completion of Requested Studies
Once studies are completed, study reports must be submitted in accordance
with either the agreement reached with FDA on study protocols or commonly
accepted scientific principles and protocols.69
63. See U.S.C. § 355a(b) (FDCA § 505A(b)) (repealed).
64. See 21 U.S.C.S. § 355a(c) (FDCA § 505A(c)).
65. Id.
66. See id. § 355a(a) (FDCA § 505A(a)), formerly 21 U.S.C. § 355a(g) (FDCA § 505A(g)).
"Pharmacokinetic studies" are studies that assess "the activity or fate of drugs in the body over a period
of time, including the processes of absorption, distribution, localization in tissues, biotransformation,
and excretion." DORLAND'S ILLUSTRATED MEDICAL DICTIONARY 1272 (28th ed. 1994). This definition
was revised slightly by the BCPA to make clear that "pediatric studies" could include neonate studies.
See 21 U.S.C.S. §§ 355a(a) (FDCA § 505A(a)); 115 Stat. at §4 and see infra note text accompanying
note 211.
67. See 21 U.S.C.S. § 355a(c) (LEXIS 1997 & Supp. 2002) (FDCA § 505A(c)).
68. See id. § 355a(d) (FDCA § 505A(d)).
69. See id. § 355a(c) (FDCA § 505A(c)).
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F. FDA Acceptance of Studies
Within 60 days of receipt of study, reports conducted pursuant to a written
agreement on protocols (or within 90 days of receipt of reports conducted without
an agreement on protocols), FDA must determine whether the reports "fairly
respond" to FDA's written request and otherwise comply with FDA's requirements
for earning extended exclusivity. 70 FDA must publish a notice of any exclusivity
award made under these provisions.
71
As discussed further below, these provisions remain in place today, except
that the pediatric list requirement for marketed drugs has been eliminated. 72 New
drugs that have not yet been approved for marketing by FDA follow the same basic
procedures, except that written requests for pediatric studies are issued during
FDA's review of the NDA for the drug, and there was never a requirement that
drug not be identified on the pediatric list before receiving a request.
73
These new pediatric exclusivity provisions of FDAMA greatly enhance the
incentives for drug sponsors to conduct pediatric studies. Even where the patient
population for the pediatric indication is small, the potential for earning pediatric
exclusivity fundamentally alters the cost-benefit calculus. The key to the new
incentives is that they leverage the potential of the adult drug market to ensure that
pediatric studies are conducted. Under the statute, the additional exclusivity
period, once earned, applies to the drug as a whole and not just to whatever
pediatric indication or formulation might result from the requested study or studies.
That is, if a company conducts pediatric studies at FDA's request on Drug X, and
earns pediatric exclusivity, Drug X will enjoy six additional months of sales free
from generic competition.
Merely providing exclusivity for the pediatric indication or formulation
would not be a substantial incentive for manufacturers. The market for the
pediatric indication or formulation might simply be too small to justify conducting
the studies. In addition, follow-on producers could circumvent exclusivity that
only covered new pediatric indications by nominally selling their product for other
indications while knowing that physicians could prescribe the product, and
70. See id. § 355a(d) (FDCA § 505A(d)). The "fairly responds" standard was confirmed in Merck
& Co. Inc. v. FDA, 148 F.Supp.2d 27 (D.D.C. 2001). In that case, FDA denied pediatric exclusivity for
Merck's drug Mevacor (lovastatin). Id. at 30. The court vacated the FDA's determination, holding, in
relevant part, that "a denial of pediatric exclusivity for failure to meet a single term of a written request
would not be in accordance with [21 U.S.C. § 355a(d)(3)], which plainly does not require compliance
with every single provision of a written request, but requires only that a pediatric study 'fairly respond'
to a written request." Id.
71. See 21 U.S.C.S. § 355a(f)(FDCA § 505A(f)).
72. See infra text accompanying notes 207-210.
73. 21 U.S.C.S. § 355a(b) (LEXIS 1997 & Supp. 2002) (FDCA § 505A(b)), formerly 21 U.S.C.
§§ 355a(a) (FDCA §§ 505A(a).
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pharmacists dispense it, for the pediatric indication.74 The FDAMA pediatric
exclusivity provisions are based on the premise that meaningful incentives can
only be provided if completing a pediatric study or studies as required for a
particular drug causes exclusivity to be extended for the drug as a whole.
Moreover, nothing in the law requires that the study or studies be successful
in demonstrating safety and effectiveness in a pediatric population to trigger the
additional six months of exclusivity. As long as the study or studies are properly
carried out and submitted to the FDA, the drug qualifies for exclusivity, even if the
results do not support approval of a pediatric formulation or new labeling. Of
course, both positive and negative data add value. For example, even if study
results are negative, they may suggest labeling that would caution against pediatric
use. The important point, however, is that the benefit of the additional six months
of exclusivity is earned once the pediatric study or studies are undertaken and
reported. This creates a more robust incentive, because it eliminates the risk that
would arise were the exclusivity contingent on a particular study outcome.
The value of the incentive for a particular drug ultimately depends on the
drug's sales. Six months of additional exclusivity have greater financial impact for
a blockbluster drug than a niche drug. Nonetheless, Congress' hope was that the
incentive as a whole would raise the stature of pediatric research within the
industry. As the congressional sponsors of the law explained:
The pediatric provisions of the FDAMA provide incentives for the
pharmaceutical industry to spend the resources necessary to develop the
infrastructure to conduct good clinical trials in children. If implemented properly
this incentive will create a 'Golden Age for Pediatric Medicine.'75
Congressional hopes notwithstanding, the realization of this lofty goal of a
"Golden Age for Pediatric Medicine" would depend in large part on FDA's
implementation of the new provisions. The statute, although detailed, provided
substantial flexibility to the agency. FDA still had to determine what drugs and
diseases should be studied, and how the necessary studies should be carried out.
Moreover, the clock was ticking. Congress required that FDA report to Congress
by January 1, 2001 on the effectiveness and performance of the FDAMA pediatric
incentive provisions.76 Barring reauthorization, the FDAMA pediatric study
provisions would have sunset on January 1, 2002. 7"
74. See id. § 355(j)(2)(A)(viii) (FDCA § 505(j)(2)(A)(viii)) (generic applicants may seek approval
for certain uses while omitting others); see also 21 C.F.R. § 314.94(a)(12)(iii)(2002).
75. Letter from Congressman Mike Bilirakis, Congressman Jim Greenwood, Senator Mike
DeWine, and Senator Christopher Dodd to Donna Shalala, Secretary of Health and Human Services 2
(Apr. 6, 1998) (on file with the Journal of Health Care Law & Policy).
76. 21 U.S.C. § 355a(k) (FDCA§ 505A(k)) (1997) [superseded by a new report requirement at 21
U.S.C.S. § 355a(m) (LEXIS 1997 & Supp. 2002) (FDCA § 505A(m))].
77. See id. § 355a(j) (FDCA§ 505A(j)) (1997) [superseded by a new sunset date at 21 U.S.C.S.
§ 355a(n) (LEXIS 1997 & Supp. 2002) (FDCA § 505A(n))].
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VI. FDA IMPLEMENTATION
FDA's implementation of the new provisions has largely come in the form of
agency guidance documents, and not through regulations. Guidance documents
state current agency interpretation of statutory requirements and reflect agency
policy, but FDA does not view them as legally binding.78
FDA's first implementation action came on March 16, 1998, when FDA
published for comment a "Draft List of Drugs for Which Additional Pediatric
Information May Produce Health Benefits in the Pediatric Population" (the Draft
Pediatric List).79 In order to develop the Draft Pediatric List, FDA solicited input
from the American Academy of Pediatrics, PhRMA, generic industry trade
associations, the National Institutes of Health, the Pediatric Pharmacology
Research Units Network, and the United States Pharmacopeia.80 The Draft
Pediatric List identified drugs by therapeutic class (e.g., cardio-renal, oncology,
anti-infective, etc.) and indicated the pediatric age groups for which additional
information is needed [neonate (birth to 1 month), infant (1 month to 2 years),
child (2 to 12 years), adolescent (12 to 16 years)].8 1
On May 20, 1998, after reviewing comments on the Draft Pediatric List, FDA
published a final "List of Approved Drugs for Which Additional Pediatric
Information May Produce Health Benefits in the Pediatric Population" (the
Pediatric List).82 The Pediatric List expanded the Draft Pediatric List to include all
drugs approved in adults for a disease or condition that occurs in pediatric
patients.83 This effectively rendered the statutory requirement that a marketed drug
appear on the list before receiving a written request a formality, because all
approved drugs with pediatric uses were deemed to be "on the list."
The Draft Pediatric List, in turn, became the basis of a priority list of drugs
for which FDA determined that additional pediatric information is needed.84 That
priority list is organized by therapeutic class and notes particular age groups for
which additional information is needed.8 5 FDA put drugs on the priority list that
78. 21 C.F.R. § 10.115 (2002).
79. See Draft List of Approved Drugs for Which Additional Pediatric Information May Produce
Health Benefits in the Pediatric Population; Availability, 63 Fed. Reg. 12,815 (Mar. 16, 1998)
(announcing availability of the Draft Pediatric List).
80. See FDA Docket No. 98N-0056, Draft List of Drugs for Which Additional Pediatric
Information May Produce Health Benefits in the Pediatric Population 1 (Mar. 9, 1998) (current version
available at http://www.fda.gov/cder/pediatric/peddrugsfinal.htm) (last visited Sept. 14, 2002).
81. Id. at 4-20.
82. See FDA Docket No. 98N-0056, List of Drugs for Which Additional Pediatric Information
May Produce Health Benefits in the Pediatric Population I (May 20, 1998) (current version available at
http://www.fda.gov/cder/pediatric/peddrugsfinal.htm) (last visited Dec. 19, 2002); Availability, 63 Fed.
Reg. 27,733 (May 20, 1998) (announcing availability of the Pediatric List) [hereinafter Pediatric List].
83. Pediatric List at 1.
84. Id. at 4-25.
85. See id
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are approved in adults for an indication that occurs in children, and that FDA also
determined meet one or more of the following criteria:
The drug, if approved for pediatric use, would be a "significant improvement
compared to marketed products labeled for use in the treatment, diagnosis, or
prevention of a disease in the relevant pediatric population;"
The drug is widely used in the pediatric population, as measured by at least
50,000 prescription mentions per year;
The drug is in a class or for an indication for which additional therapeutic or
diagnostic options for the pediatric population are needed.86
After finalizing the Pediatric List, on July 7, 1998, FDA issued a guidance
document entitled "Guidance for Industry: Qualifying for Pediatric Exclusivity
Under Section 505A of the Federal Food, Drug, and Cosmetic Act" (the Section
505A Guidance).87 This guidance document was revised in September 1999, and
sets forth FDA's primary interpretation of the FDAMA pediatric incentive
provisions, as well as its procedures for administering the new statutory scheme.88
The Section 505A Guidance makes clear that FDA views its statutory mandate as
seeking all studies that could potentially result in beneficial pediatric information.
FDA stated that it would issue written requests seeking "all necessary pediatric
information for an active moiety., 89 FDA's intent to seek broad-ranging pediatric
studies is also reflected in the series of sample written requests that FDA has
issued for different therapeutic categories.
90
In keeping with the agency's intent to require that companies perform
extensive pediatric trials in order to qualify for pediatric exclusivity, the agency
has construed the pediatric exclusivity benefit in an expansive manner. Under the
Section 505A Guidance, if a sponsor conducts pediatric trials and earns pediatric
exclusivity, the exclusivity will apply to all of the sponsor's drug products that
86. Id. at 2.
87. See Guidance for Industry on Qualifying for Pediatric Exclusivity; Availability; Request for
Submissions, 63 Fed. Reg. 36,707 (July 7, 1998) (announcing availability of the Section 505A
Guidance).
88. See Guidance for Industry on Qualifying for Pediatric Exclusivity; Availability; Request for
Submissions, 64 Fed. Reg. 54,903 (Oct. 8, 1999) (announcing availability of revised Section 505A
Guidance); FDA Guidance for Industry: Qualifying for Pediatric Exclusivity Under Section 505A of
the Federal Food, Drug, and Cosmetic Act (Sept. 1999), available at
http://www.fda.gov/cder/guidance2891fnl.pdf (last visited Dec. 19, 2002) [hereinafter Section 505A
Guidance]. Additional procedures are set forth in a document published by FDA's Center for Drug
Evaluation and Research on October 6, 1998 to guide FDA staff. See Manual of Policies and
Procedures ("MAPP") § 6020.6 (Oct. 6, 1998) ("Process for Handling Pediatric Exclusivity"), available
at http://www.fda.gov/cder/mapp.htm (last visited Dec. 16, 2002).
89. Section 505A Guidance at 5.
90. CTR. FOR DRUG EVALUATION RES., PEDIATRIC MED., U.S. FDA, FDA MODERNIZATION ACT,
SAMPLE WRITTEN REQUESTS, available at http://www.fda.gov/cder/pediatric (last visited Sept. 14,
2002).
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contain the active moiety studied.9 1 That means that if a sponsor conducts a study
on a particular drug formulation, the exclusivity earned could apply to other
formulations, provided that they contain the active moiety that was part of the
study.
Two other aspects of the Section 505A Guidance are worth special mention.
First, FDA stated that a sponsor can use studies conducted by third parties and
previously existing data to respond to a written request and earn pediatric
exclusivity.92 Existing data may not be used if "the data are already known to
provide no useful information," or if the data have already been submitted to FDA
as part of an application for a new drug approval.9 3 This policy ensures that there
is an incentive for drug sponsors not only to conduct new studies, but also to
collect and analyze existing data from all available sources to determine whether
the data could support expanded pediatric use of a drug.
Second, FDA stated that pediatric studies once completed must be reported to
FDA in the form of an NDA or an NDA supplement (e.g., a supplement for new
labeling).94 FDA confirmed that the statute does not require that an NDA or
supplement be approved in order to earn pediatric exclusivity, since the exclusivity
is based solely on the completion and submission of the studies.95 Nonetheless, by
requiring that sponsors submit study reports in the form of an NDA or supplement,
FDA further ensured that the studies would ultimately yield FDA-approved
pediatric information, either in the form of new pediatric formulations or new
pediatric labeling.
FDA's various implementation measures filled the gaps that were not
addressed in the legislation itself. Consistent with Congress' stated intent, FDA's
policies reflect a broad interpretation of the statutory provisions and are designed
to produce the maximum amount of pediatric information. However, not all
interested parties appreciated the FDA's approach, including, most notably,
generic drug manufacturers. Generic drug makers stood to lose the most from
these provisions because their products faced delayed approvals due to grants of
pediatric exclusivity, and they responded by challenging FDA's actions in court.
91. Section 505A Guidance at 13. FDA defines "active moiety" as the "molecule or ion, excluding
those appended portions of the molecule that cause the drug to be an ester, salt ... or other noncovalent
derivative ... of the molecule, responsible for the physiological or pharmacological action of the drug
substance." 21 C.F.R. § 314.108(a) (2002). For a given active moiety, there may be several different
particular product formulations (e.g., different dosage forms or dosage strengths). Id.
92. Section 505A Guidance at 4.
93. Id. ("Therefore, FDA will not generally accept studies conducted prior to issuance of a Written
Request unless the studies would potentially support a change in the labeling to incorporate pediatric
information.").
94. Id. at 11.
95. Id.
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A. National Pharmaceutical Alliance v. Henney
On February 19, 1999, just as FDA's implementation of the statute was
beginning to take effect, two generic drug trade associations-the National
Pharmaceutical Alliance (NPA) and the Generic Pharmaceutical Industry
Association (GPIA)-jointly filed suit against FDA in the United States District
Court for the District of Columbia to challenge FDA's implementation of the
pediatric incentive provisions of FDAMA.96 NPA and GPIA charged that FDA
implemented Section 111 of FDAMA in a manner that violates the procedural
requirements of the Administrative Procedures Act (APA) 9 7 and the substantive
provisions of FDAMA itself.
Among other things, NPA and GPIA alleged that FDA's publication of the
Pediatric List failed to comply with FDAMA's requirements regarding 1)
consultation with pediatric experts, 2) assessment of whether a drug might produce
health benefits, and 3) prioritization of the list.98 They also took aim at the Section
505A Guidance, arguing that it was a "substantive rule" that could only be issued
with notice and comment rulemaking, and that it conflicted with FDAMA's
standards regarding the scope of an extended exclusivity award and the types of
studies that can qualify for exclusivity.99 Based on these allegations, NPA and
GPIA requested that the Court declare the Pediatric List, Section 505A Guidance,
existing written requests, and existing pediatric exclusivity awards invalid, and
require FDA to rescind each for conflict with FDAMA. They also asked that FDA
be required to suspend all future actions related to Section 111 of FDAMA until
FDA promulgated final regulations pursuant to notice and comment rulemaking
and reissued a proper pediatric list.
On April 20, 1999, the court rejected these claims across the board in the
context of plaintiffs' motion for a preliminary injunction, and the case did not
proceed any further. 100 The court held in particular that FDA's moiety-based
interpretation of the scope of pediatric exclusivity grants was not at odds with the
statute, and was entitled to deference.' 0' The court further held that FDA was free
to implement the statute on the basis of guidance documents, without issuing
regulations through formal notice and comment rulemaking. 10 2  This holding
cleared the way for FDA to proceed in accordance with the policies and procedures
it had originally set out, and the agency has done precisely that.
96. Nat'l Pharmaceutical Alliance v. Henney, 47 F.Supp.2d 37 (D.D.C. 1999).
97. 5 U.S.C. § 553 (2001).




102. Id. at 40-4 1.
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B. The Current Pediatric Initiative Part 2: The Stick of the Pediatric Rule
A little over a year after Congress enacted FDAMA, FDA finalized the
Pediatric Rule it had proposed earlier.10 3 The rule took effect on April 1, 1999, and
required drug sponsors to submit specified pediatric study data by December 2000,
unless the sponsor obtained a waiver or deferral.' 4 These requirements were new
and unprecedented in that they compelled drug sponsors to perform research
neither proposed by the sponsor nor related to a use for which the sponsor was
seeking approval. The requirements were recently invalidated by a federal district
court, and FDA was enjoined from enforcing the rule.10 5 At the same time, bills
have been introduced in Congress to "codify" the Pediatric Rule, or otherwise
grant FDA the authority to require pediatric studies. In light of all of these recent
developments, the precise status of the Pediatric Rule was in doubt at the time of
the writing of this article.
VII. THE REQUIREMENTS
A. New Products Not Yet Approved
Under the rule, all drug and biologics applications for a new active
ingredient, new indication, new dosage form, new dosing regimen, or new route of
administration had to contain data adequate to assess the safety and effectiveness
of the product for the claimed indications in all relevant pediatric subpopulations,
and support dosing and administration in all pediatric subpopulations for which the
product is safe and effective, unless FDA granted a waiver or a deferral.,0 6 These
requirements only applied to indications that were being sought for adults. Data on
safety and effectiveness in pediatric patients were not required for unapproved or
unclaimed indications, even for a product widely used in pediatric patients for
those indications. 10 7 In addition, drugs for an indication or indications with orphan
designation under the Orphan Drug Act were exempt from the rule. 10 8
FDA specified what particular pediatric data must be required for a product
on a case-by-case basis. Where the course of the disease and the effects of the
product are sufficiently similar in adults and pediatric patients, FDA may have
permitted the required data on pediatric safety and effectiveness to be supported by
103. 63 Fed. Reg. 66,632 (Dec. 2, 1998).
104. Id.
105. Ass'n of Am. Physicians and Surgeons, Inc., et al. v. U.S. FDA, et al., No. CIVA.00-02898,
2002 WL 31323411, *15 (D.D.C. Oct. 17, 2002).
106. 21 C.F.R. §§ 314.55(a), 601.27(a) (2002).
107. 63 Fed. Reg. at 66,634.
108. 21 C.F.R. §§ 314.55(d), 601.27(d) (2002). Orphan drug exclusivity is granted as a special
incentive to drugs that treat diseases or conditions with small patient populations. See 21 U.S.C.
§ 360cc(a) (FDCA § 527(a)).
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effectiveness data in adults and additional information such as dosing,
pharmacokinetic and safety data in pediatric patients.10 9 If data from one age
group could be extrapolated to another, studies may not have been needed in each
pediatric age group. 1 0
Pediatric studies were required for each age group in which the product
would provide a "meaningful therapeutic benefit" or would be used in a
"substantial number of pediatric patients" for the indications claimed by the
manufacturer. II (The definitions of "meaningful therapeutic benefit" and
"substantial number of pediatric patients" are discussed in the waiver section
below). FDA defined "relevant age groups" flexibly and did not adhere to fixed
categories. 112  For products that offer a meaningful therapeutic benefit,
manufacturers were required to develop pediatric formulations (if needed) for
those age groups in which studies were required, unless they could demonstrate
that reasonable attempts to develop a pediatric formulation had failed." 3
B. Already Marketed Products
While the rule created a default presumption that all new applications would
include pediatric data, FDA stated that it would only require pediatric studies for
already marketed products in "compelling circumstances."'"14  When FDA
promulgated the Pediatric Rule, it estimated that it would require studies in
approximately two marketed drugs per year." 5 In fact, it had never exercised this
authority.
Nevertheless, under the rule, FDA could require pediatric studies for a
product that is already marketed if: (1) the absence of adequate labeling could pose
significant risks to patients, and (2) the product is used in a substantial number of
pediatric patients, or provides a meaningful therapeutic benefit over existing
treatments for pediatric patients." 6 As with new products, the applicant may have
been required to submit evidence to support dosage and administration in some or
all pediatric subpopulations, including neonates, infants, children, and
adolescents.'17 For products that represent a meaningful therapeutic benefit over
existing therapies, the applicant also may have been required to develop a pediatric
109. 21 C.F.R. §§ 314.55(a), 601.27(a) (2002).
110. Id.
111. Id.
112. 63 Fed. Reg. at 66,634.
113, 21 C.F.R. §§ 314.55(a), (c)(3)(iv); §§ 601.27(a), (c)(3)(iv) (2002).
114. 63 Fed. Reg. at 66,634 ("FDA intends to reserve its authority to require studies of marketed
drugs and biologics to situations in which the compelling circumstances described in the regulation are
present.").
115. Id. at 66,654.
116. 21 C.F.R. § 201.23(a) (2002).
117. Id.
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formulation, unless reasonable attempts to produce a pediatric formulation have
failed.' 18
These requirements applied to generic manufacturers as well. Where FDA
required pediatric studies on a multi-source marketed drug, each manufacturer of
that drug, including the generic, would have been required to satisfy the study
requirement. 19 FDA would have encouraged all manufacturers to fund an
appropriate study jointly. 2 °
C. Deferrals
For new products seeking approval, FDA may have, on its own initiative or
at the request of an applicant, permitted the submission of some or all of the
required pediatric information to be deferred until after a product's approval.'
2 1
For example, deferral may have been granted if the product was ready for approval
in adults before studies in pediatric patients were complete, or if pediatric studies
should have been delayed for ethical or other reasons until additional safety and
effectiveness data have been collected. Deferral requests had to be accompanied
by a description of the planned or ongoing studies and evidence that the studies
were being or would be conducted with due diligence.' 22  FDA could have
approved the product for use in adults subject to the requirement that the applicant
submit the required pediatric assessments within a specified time.1
23
FDA stated that it would be less amenable to delays in obtaining pediatric
data for products aimed at life-threatening diseases for which adequate therapy
does not exist. FDA envisioned studies for such products beginning as soon as
preliminary safety data in adults were available.' 24 For less critical products, FDA
envisioned studies beginning when additional safety and/or effectiveness data were
available from initial well-controlled trials in adults. 25 FDA did not believe that
early study or use in pediatric patients was appropriate for "me too" products in a
product class that already contains an adequate number of approved products with
pediatric labeling.' 26 FDA may have required that the pediatric use section of the
approved labeling of a "me too" product contain a statement recommending
preferential use of other drugs that are adequately labeled for pediatric use. 127
118. 21 C.F.R. §§ 201.23(a), (c)(2)(iv) (2002).
119. 63 Fed. Reg. at 66,654.
120. Id.
121. 21 C.F.R. §§ 314.55(b), 601.27(b) (2002).
122. Id.
123. 63 Fed. Reg. at 66,642.
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D. Waivers
In order to obtain a waiver of the study requirement for some or all pediatric
age groups, the sponsor of a new product application had to demonstrate that 1) the
product did not represent a meaningful therapeutic benefit for pediatric patients
over existing treatments, and 2) the product was not likely to be used in a
substantial number of pediatric patients.128 The study requirement would apply if
the product offered a meaningful therapeutic benefit, even if it was not used in a
substantial number of pediatric patients. The study requirement also would apply
if the product was used in a substantial number of pediatric patients, even if the
product did not offer a meaningful therapeutic benefit. The holder of a marketed
product application seeking a waiver had to satisfy the above criteria and show that
the absence of adequate labeling could not pose significant risks to pediatric
patients. FDA ordinarily would not consider the cost of conducting studies as a
factor in determining whether to grant a waiver.129
FDA's definition of "meaningful therapeutic benefit" was based on the
definition of a "priority" drug used by FDA's Center for Drug Evaluation and
Research. 130 FDA considered a product to have a meaningful therapeutic benefit if
it would be a significant improvement in the treatment, diagnosis, or prevention of
a disease compared to marketed products that were approved and adequately
labeled for that use in the relevant pediatric population.13 ' If there were no existing
products, the new product would usually be considered to have a meaningful
therapeutic benefit. Improvement over existing products would be demonstrated
by 1) evidence of increased effectiveness in treatment, prevention, or diagnosis of
disease, 2) elimination or substantial reduction of a treatment-limiting drug
reaction, 3) documented enhancement of patient compliance, or 4) evidence of
safety and effectiveness in a new subpopulation 3 2 A product would also be
considered to provide a meaningful therapeutic benefit if it was in a class of
products or for an indication for which there were few products labeled for
pediatric use and more therapeutic options were needed, even if the product did not
meet FDA's criteria for priority drugs.
133
FDA considered a product to be used in a "a substantial number of pediatric
patients" if there were 50,000 patients with the disease or condition for which the
product was indicated, as determined by physician mentions per year in the IMS
National Disease and Therapeutic Index.' 34 A partial waiver would be available
128. 21 C.F.R. §§ 314.55(c)(2)(i), 601.27(c)(2)(i) (2002).
129. 63 Fed. Reg. at 66,647.




134. Id. at 66,646-47.
[VOL. 6:34
2002] LEGISLATIVE AND REGULATORY INITIATIVE TO EXPAND RESEARCH 55
for a particular pediatric age group if up to 15,000 patients in that age group were
affected by the disease or condition.'
35
FDA would also waive the pediatric study requirement for new and marketed
products where: 1) the required studies were impossible or highly impractical (for
example, because the population was too small or geographically dispersed), 2) the
product was likely to be unsafe or ineffective in pediatric patients, or 3) reasonable
efforts to develop a pediatric formulation (if one is needed) failed.13 6
E. Pediatric Use Section of an Application
The final rule required that a new product application contain a pediatric use
section. This section briefly summarized the pediatric studies conducted and
referenced the full description of each study provided elsewhere in the
application. 1
37
1. Planning Pediatric Studies
The new rule revised FDA's investigational new drug regulations to provide
that all investigational new drug applications (INDs) should contain information on
the sponsor's plans for assessing pediatric safety and effectiveness. 38 FDA would
then meet with sponsors at various points in the drug investigation process to
discuss plans for the pediatric studies. 39 FDA emphasized the need for earlier




Sponsors of approved products were requested to include in their annual
reports to FDA the following information: 1) a brief summary of whether labeling
supplements for pediatric use had been submitted and whether new studies in the
pediatric population to support labeling had been initiated, along with (if possible)
an estimate of patient exposure to the product by dosage form with reference to
pediatric populations (neonates, infants, children, and adolescents), 2) an analysis
135. Id. at 66,648. FDA identified the following particular diseases for which waivers would likely
be granted because they rarely occur in pediatric patients, if at all:
Alzheimer's disease, age-related macular degeneration, prostate cancer, breast cancer, non-germ cell
ovarian cancer, renal cell cancer, hairy cell leukemia, uterine cancer, lung cancer, squamous cell
cancers of the oropharynx, pancreatic cancer, colorectal cancer, basal cell and squamous cell cancer,
endometrial cancer, osteoarthritis, Parkinson's disease, amyotrophid lateral sclerosis, arteriosclerosis,
infertility, symptoms of menopause. Id.
136. 21 C.F.R. §§ 314.55(c)(2)(ii), (3)(iv); §§ 601.27(c)(2)(ii), (3)(iv) (2002).
137. 21 C.F.R. § 314.50(d)(7) (2002).
138. See id. § 312.23(a)(1)(iii) (2002).
139. See id. §§ 312.47, 312.82 (2002).
140. See id. § 312.82 (2002).
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of available pediatric safety and efficacy data and changes proposed to product
labeling based on such data, and 3) a report on the status of any post-marketing
pediatric studies that were required or agreed to, including whether the studies
were initiated, ongoing (with projected completion date), completed (including
completion date), or completed with results submitted to FDA (including date).141
3. Pediatric Committee
When it promulgated the Pediatric Rule, FDA announced its intention to
convene a panel of pediatric experts to provide advice on a range of issues,
including: 1) FDA's implementation of all aspects of the final rule, including its
waiver and deferral decisions, 2) identification of marketed products that meet the
criteria for requiring studies, 3) identification of diseases or conditions for which
additional therapeutic options are needed, 4) consideration of ethical issues raised
by clinical trials in pediatric patients, 5) the design of trials and analysis of data for
specific products or classes of products, and 6) assessment of the progress of
individual studies. 142 The panel was in fact convened and met on these and other
issues.
4. Enforcement
FDA's main mechanism for enforcing the requirements was the filing of an
action in federal court asking the court to find that a product was misbranded or an
unapproved new drug, or an unlicensed biologic, and issue an injunction requiring
the submission of an assessment of pediatric safety and effectiveness for the
product. 143 Violations of a court-ordered injunction could then result in contempt
proceedings and civil or criminal penalties. FDA stated that it did not intend,
except in rare circumstances, to disapprove or withdraw approval of a product
whose manufacturer violated the requirements imposed under the new rule.' 44
VIII. RELATIONSHIP OF THE PEDIATRIC RULE TO FDAMA
FDA's primary reason for finalizing the Pediatric Rule even though FDAMA
had been enacted was to address perceived gaps in the statute. As FDA explained,
the FDAMA pediatric exclusivity provisions do not apply to products for which no
patent or other exclusivity protection is currently in existence that can receive a
six-month extension. 4 5 Biologics and certain antibiotics also are not eligible to
receive exclusivity under FDAMA. 146 In addition, the FDAMA provisions are
141. See id. §§ 314.81(b)(2), 601.70 (2002).
142. 63 Fed. Reg. at 66,656.
143. Id. at 66,655.
144. Id.
145. Id. at 66,633.
146. Id.
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voluntary, and FDA was thus concerned that sponsors simply might elect not to
respond to a written request even with the potential for earning pediatric
exclusivity, or that studies would be pursued but ultimately insufficient to produce
needed pediatric labeling. 1
47
The Pediatric Rule ensured that FDA had a mechanism to obtain pediatric
assessments where the FDAMA exclusivity incentive either did not apply or was
ineffective. For marketed drugs, FDA made clear that it would provide
manufacturers an opportunity to submit studies voluntarily under FDAMA before
determining whether it would require any pediatric studies. 148 The Pediatric Rule
presumptively applied to all new applications, but any drug studies that were
required (whether for new or marketed drugs) were also eligible for extended
exclusivity under FDAMA. 149 In this way, the Pediatric Rule reinforced FDAMA
to ensure that studies would be undertaken.
In one key respect the Pediatric Rule was actually more limited than
FDAMA. FDA was clear that the Pediatric Rule only required pediatric
assessments related to adult indications for which the drug sponsor had received or
was seeking approval. 150 FDAMA has no such limitation, and written requests can
be issued for studies on new or previously unclaimed indications.
A. Ass 'n ofAmerican Physicians and Surgeons v. FDA
Just as FDA's implementation of the FDAMA exclusivity provisions came
under legal attack, so too the Pediatric Rule was challenged in the courts. When
FDA issued the rule, it asserted that it possesses the legal authority to require
pediatric studies under the following general provisions of the Federal Food, Drug
and Cosmetic Act (FDCA) and Public Health Service Act (PHSA):
" Requirement of adequate directions for use and prohibition of false or
misleading labeling (including labeling that fails to reveal material facts
related to customary or usual use);' 5 1
" Authorization to bring enforcement action against a drug not recognized as
safe and effective or approved for the conditions prescribed, recommended,
or suggested in the labeling;
5 2
" Prohibition on misbranding or introducing an unapproved new drug into




148. id. at 66,634.
149. 21 U.S.C.S. § 355a(h) (LEXIS 1997 & Supp. 2002) (FDCA § 505A(h)), formerly 21 U.S.C. §
355a(i) (FDCA § 505A(i)); see also 63 Fed. Reg. at 66,633.
150. 63 Fed. Reg. at 66,634.
151. See 21 U.S.C. §§ 321(n), 352(a), 352(f), 355(d)(7) (FDCA §§201(n), 502(a), 502(f),
505(d)(7)); see also 21 C.F.R. § 201.5 (2002).
152. 21 U.S.C. §§ 321(p), 331(a), 331(d), 355(a) (FDCA §§ 201(p), 301(a), 301(d), 505(a)).
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" Prohibition on drugs that are dangerous to health when used in the manner
suggested in their labeling;
154
" Authorization to impose conditions on the investigation of new drugs,
including conditions related to the ethics of an investigation and to require
post-marketing reports;1
55
" Authorization to issue regulations for the efficient enforcement of the
FDCA; 156 and
" Requirement that biological products be safe, pure, and potent.
157
FDA also cited a provision in FDAMA, which states that pediatric studies
required by FDA will qualify for extended exclusivity as confirmation of its
authority to compel pediatric studies.
15 8
Notwithstanding the long list of provisions cited by FDA, serious questions
exist about FDA's authority to require a study that is not related to an indication or
claim sought by the product sponsor. The cited provisions do not give FDA any
express power to mandate that studies be performed for indications for which a
sponsor has not sought approval. Moreover, FDA had never previously interpreted
these provisions in the expansive manner that it was now suggesting, or asserted
the open-ended authority that it now claimed to possess. Indeed, in a famous
quote, former FDA Commissioner David Kessler stated:
Despite the ardent desire of the FDA to increase pediatric indications, I need
to acknowledge the limits of FDA's authority. It is our job to review drug
applications for indications suggested by the manufacturer. We do not have the
authority to require manufacturers to seek approval for indications which they have
not studied .... Thus, as a matter of law, if an application contains indications
only for adults, we're stuck. 159
B. Commissioner Kessler's remarks obviously do not reflect the FDA's current
position, as stated in the Pediatric Rule
The question of whether or not FDA has the legal authority to mandate
pediatric studies was ultimately presented in the courts. On December 4, 2000, a
153. See id. §§ 321(g), 331(a), 331(d), 331(k), 332, 334 (FDCA §§ 201(g), 301(a), 301(d), 301(k),
302, 304).
154. See id. § 3520) (FDCA § 5020)).
155. See id. § 355(i), 355(k) (FDCA § 505(i), 505(k)).
156. See id. § 371(a) (FDCA § 701(a)).
157. See Public Health Service Act, Pub. L. ch. 373 § 35 1(d), § 351, 58 Stat. 702-03 (1944);
(codified as amended 42 U.S.C. § 262 (2000)) [hereinafter PHSA].
158. 21 U.S.C.S. § 355a(h) (LEXIS 1997 & Supp. 2002) (FDCA § 505A(h)), formerly 21 U.S.C. §
355a(i) (FDCA § 505A(i)); see also 63 Fed. Reg. 66,633.
159. Remarks by David A. Kessler, at the Annual Meeting of the American Academy of Pediatrics
1,4 (Oct. 14, 1992) (on file with the Journal of Health Care Law & Policy).
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group of not-for-profit organizations filed suit in the United States District Court
for the District of Columbia seeking repeal of the Pediatric Rule on the grounds
that it exceeds FDA's statutory authority and is otherwise unlawful. 60  The case
is Assn 'n of American Physicians and Surgeons v. FDA, and on October 17, 2002,
the district held that FDA exceeded its statutory authority in promulgating the
Pediatric Rule, and enjoined FDA from enforcing the Rule.' 61 The court then
proceeded to analyze the text of the FDCA, prior FDA application of the statute,
and related statutory provisions, including in particular the pediatric exclusivity
provisions from FDAMA and the BPCA.
As to the text of the FDCA, the court concluded that if Congress had intended
to grant FDA authority to require drug manufacturers to study their products for
unclaimed uses that it "would likely have spoken more clearly."' 162 The labeling
provisions of the FDCA require that a product's labeling provide directions related
to the product's conditions of use, including those that are "customary or usual"
and those that are "prescribed, recommended, or suggested" in the product's
labeling.' 63 The court held that these provisions regarding labeling do not support
FDA's requirement that a drug manufacturer conduct new studies and develop new
formulations to support pediatric uses that the manufacturer is not seeking for the
product, and may in fact be specifically disclaiming on the label. 164 The court also
found that other provisions of the FDCA are in tension with the Pediatric Rule.
165
Next, the court held that the Pediatric Rule contradicts prior FDA tradition,
because the agency "has repeatedly stated that it may only regulate claimed uses of
drugs, not all foreseeable or actual uses.' 66 According to the court, if FDA's
argument were accepted, "the door would be open to FDA's regulation of all off-
label uses, based solely on the manufacturer's knowledge that those uses are
common-place.' 67  Such an open-ended grant of authority would contravene
Congress' intent, the court said, and "would eviscerate the long-established
foundation of federal food and drug law, which allows, not the FDA, but the
'manufacturer of the article, through his representations in connection with its sale,
[to] determine the use to which the article is to be put." 168
160. Ass'n of Am. Physicians & Surgeons, Inc., et al. v. FDA, et al., No. 00-CV-2898 (D.D.C. Dec.
4, 2000).
161. See Ass'n of Am. Physicians & Surgeons, Inc., et al., v. U.S. FDA, et al., No. CIVA.00-02898,
2002 WL 31323411, *7 (D.D.C. Oct. 17,2002).
162. Id. at *8.
163. Id. at *7-*9.
164. Id. at *8-*11.
165. Id. at *11.
166. Id.
167. Id.
168. Id. (quoting S. Rep. No. 73-493, at 3 (1934)).
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Finally, the Court concluded that the Pediatric Rule conflicts with the
pediatric incentive provisions of FDAMA and the BPCA. 169 The court noted that
Congress neither expressly rejected nor endorsed the Pediatric Rule, and found the
available legislative history to be contradictory. 70 However, the court concluded
that the statutory pediatric exclusivity provisions and the study requirements of the
Pediatric Rule are fundamentally incompatible. 171 In the court's words, "Congress
adopted an incentive scheme while the FDA adopted a command and control
approach.",172 FDA had until December 16, 2002 to appeal the court's decision.'73
In the interim, FDA was subject to the court's injunction prohibiting enforcement
of the Pediatric Rule.1
74
IX. RECENT DEVELOPMENTS
While the Ass 'n of American Physicians and Surgeons case was progressing,
a bill was introduced in the Congress that would "codify" the Pediatric Rule and
provide FDA the express statutory authority to require pediatric trials. Senator
Clinton introduced the bill on August 1, 2002, and it has been reported out of the
Senate Committee on Health, Education, Labor, and Pensions.' 75 Nothing in the
Ass'n of American Physicians and Surgeons decision on its face, would bar
Congress from enacting such a bill.
Senator Clinton introduced the bill after FDA announced in a March 18, 2002
filing in the Ass 'n of American Physicians and Surgeons case that it intended to
"stay" the rule for two years to provide an opportunity to assess how the provisions
of the newly enacted BPCA and the Pediatric Rule relate to one another, and
"whether, in light of the broader scope of the BPCA, the Pediatric Rule remains
necessary."' 76 FDA later reversed that position and reaffirmed the validity of the
Pediatric Rule.' 77 Whether FDA would have ultimately modified the Pediatric
Rule in some respect following enactment of the BPCA is unclear, although FDA
solicited public comments on how it should proceed. 178 As the next section
discusses, the BPCA addresses many of the perceived gaps in the FDAMA
exclusivity provisions, including most notably the coverage of off-patent drugs. It
169. Id. at *12.
170. Id. at *13.
171. Id. at *13-*14.
172. Id. at *13.
173. See Fed. R. App. P. 4(a)(l)(B).
174. Ass 'n ofAm. Physicians & Surgeons, 2002 WL at *15.
175. S. 2394, 107th Cong. § 505B (2002).
176. Defendants' Motion for Stay of Proceedings, Ass'n of Am. Physicians & Surgeons, No. 00-
2898 (HHK) at 2.
177. Defendants' Notice of Clarification Regarding Defendants Motion for Stay of Proceedings,
Ass 'n ofAm. Physicians & Surgeons, No. 00-2898 (HHK) at 1.
178. Obtaining Timely Pediatric Studies of and Adequate Pediatric Labeling for Human Drugs and
Biologics, 67 Fed. Reg. 20,070 (Apr. 24, 2002).
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could thus serve some of the same functions that the Pediatric Rule was intended to
serve.
A. The Current Pediatric Initiative Part 3:
The Best Pharmaceuticals for Children Act
On January 4, 2002, President Bush signed into law the Best Pharmaceuticals
for Children Act (BPCA), 179 reauthorizing the pediatric exclusivity provisions of
FDAMA until October 1, 2007.180 The pediatric exclusivity provisions of
FDAMA were not without detractors. Some charged that drug sponsors were
conducting relatively small pediatric studies in exchange for large windfalls in the
form of six months of additional exclusivity, particularly on blockbuster drugs
where six months of additional sales without generic competition translates into
large dollar amounts.' 8' Others maintained that studies were not translating into
new FDA-approved labeling, because drug sponsors received the additional
exclusivity as soon as they submitted responsive studies to FDA, and thus did not
have an incentive to make timely labeling changes based on the study results.' 82
For its part, FDA reported to Congress that the FDAMA incentives were
working. In the agency's words, "the industry's response has been vigorous and
the public health benefits have been extensive."'' 83 FDA noted that it had issued
157 written requests for pediatric studies as of September 2000, and sponsors had
conducted or planned to conduct 80 per cent or more of the studies FDA
requested. 84 Some 58 studies had already been completed and reviewed at least in
part by the agency. 85  These studies produced efficacy, safety, and dosing
information for a wide range of different therapies, and the information was being
captured in new FDA-approved labeling.' 86 These public health benefits came at
the cost of delayed generic drug approvals, but FDA estimated that the provisions
added only one half of one per cent to national spending on pharmaceuticals.' 87
Accordingly, FDA recommended that the FDAMA incentives be renewed with
179. Pub. L. No. 107-109, 115 Stat. 1408 (2002).
180. 21 U.S.C.S. § 355a(n) (LEXIS 1997 & Supp. 2002) (FDCA § 505A(n)). In order to be eligible
for six months of pediatric exclusivity, before October 1, 2007 there must be an application for the drug
accepted for filing and a written request for pediatric studies issued. Id. Pediatric studies may then be
conducted and submitted after October 1, 2007. Id.
181. See, e.g. Rachel Zimmerman, Pharmaceutical Firms Win Big on Plan to Test Adult Drugs on
Kids, THE WALL ST. J., Feb. 5, 2001, at Al.
182. S. REP. No. 107-79, at 8-9 (2001).
183. FDA Report to Congress, supra note 26, at 8.
184. Id.
185. Id.
186. Id. at 9-12.
187. Id. at 17.
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minor modifications: "[The program's] unprecedented success in generating
needed pediatric studies should not be forfeited."' 88
Based perhaps on FDA's strong endorsement, Congress left the basic features
of the pediatric exclusivity provisions essentially intact when it enacted the BPCA.
FDA must still issue a written request for pediatric studies, the drug sponsor must
conduct the studies in a timely manner and in a way that "fairly responds" to the
written request, the drug sponsor still earns six months of exclusivity on all
existing patent and exclusivity periods for products containing the active moiety
studied, etc. There were proposals in the Congress to amend these basic features
of the exclusivity provisions-for example, to create a tiered system of exclusivity
with six months of exclusivity for drugs with certain sales, and lesser periods of
exclusivity for drugs with greater sales-but these proposals were rejected. 89
At the same time, Congress did address some of the criticisms of FDAMA.
In particular, Congress created new programs administered through NIH to address
off-patent drugs and other perceived gaps in the FDAMA exclusivity scheme.
Congress also added new provisions to ensure that studies conducted under
FDAMA would lead to timely labeling changes, even though exclusivity itself
would continue to be awarded upon the submission of responsive studies.
Following is a summary of these provisions from the BPCA.
B. NIH Funded Pediatric Studies
1. Off-Patent/Off-Exclusivity Drugs
The law creates a new section 4091 of the Public Health Service Act, to
establish a publicly funded program administered by NIH for awarding contracts to
study off-patent/off-exclusivity drugs in pediatric patients. 90 Two hundred million
dollars in public appropriations are authorized for contract awards. 19' Contracts for
these studies will be awarded to third parties (e.g., pediatric research centers), and
drug sponsors are not eligible.192 Based on the third-party study results, FDA will
negotiate appropriate labeling changes with the drug sponsors. 93 In addition, if a
188. Id. at 23.
189. The Senate passed the "Best Pharmaceuticals for Children" Act (S. 1789) by voice vote on
December 12, 2001. The House of Representatives took up and passed S. 1789 by voice vote on
December 18, 2001. Senate bill S. 1789 was the House-Senate conference agreement on the
reauthorization legislation. The original Senate bill was S. 838 and passed by voice vote on October 18,
2001. The original House bill was H.R. 2887 and passed under suspension of the rules by a 338-86
vote on November 15, 2001. The primary legislative history for the law consists of Senate Report 107-
79 and House Report 107-277.
190. 42 U.S.C.S. § 284m (Law Co-op 1994 & Supp. 2002) (PHSA § 4091).
191. See id. § 284m(d) (PHSA § 409I(d)).
192. See id. § 284m(b) (PHSA § 4091(b)).
193. See id. § 284m(c)(7)-(l 1) (PHSA § 4091(c)(7) -(11)).
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pediatric study completed under a public contract indicates that a formulation
change is necessary and FDA agrees, FDA must send a "nonbinding letter of
recommendation" to all drug sponsors to that effect. 194  The mechanism for
effectuating labeling changes based on publicly funded studies is described in the
"dispute resolution" section below.
2. On-Patent/On-Exclusivity Drugs
Related provisions exist in the law to study drugs that still have remaining
patent or exclusivity protections where the sponsor decides not to perform pediatric
studies in response to a written request from FDA. The new law requires that a
recipient of a written request under the FDAMA provisions for pediatric studies on
an already marketed drug inform FDA within 180 days of receiving the written
request whether the recipient will perform the requested studies, and, if so, when
the studies will be initiated; 19 previously, no response to a written request was
required. If the holder does not agree to do the studies (or fails to respond within
180 days), and FDA determines that there is a continuing need for pediatric
information, FDA must refer the drug for study to the Foundation for the National
Institutes of Health and give public notice of the name of the drug, the name of the
manufacturer, and the indications to be studied under the referral. 1
96
Under section 499 of the Public Health Service Act, as amended by this law,
the Foundation for the National Institutes of Health is authorized to receive gifts,
grants, and donations, and to use those funds for the issuance of research grants. 197
After receiving a referral from FDA for pediatric studies, the Foundation must
issue a proposal for a grant to conduct the requested studies, unless the Foundation
certifies that it does not have the necessary funds. 98 If the Foundation makes such
a certification, the drug is referred for inclusion on the list of otherwise off-
patent/off-exclusivity drugs to be studied with publicly funded contract awards
administered by NIH. 199 Under the law, not all declined written requests must be
referred to the Foundation. 200
When a pediatric research grant is issued by the Foundation, the recipient of
the grant must agree to provide NIH and FDA with reports and data at the
conclusion of the studies.20i FDA shall then "take appropriate action," including
194. See id. § 284m(c)(12) (PHSA § 4091(c)(12)).
195. 21 U.S.C.S. § 355a(d)(4)(A) (LEXIS 1997 & Supp. 2002) (FDCA § 505A(d)(4)(A)).
196. See id. § 355a(d)(4)(B) (FDCA § 505A(d)(4)(B)).
197. 42 U.S.C.S. § 290b (Law Co-op 1994 & Supp. 2002) (PHSA § 499).
198. 21 U.S.C.S. § 355a(d)(4)(C) (FDCA § 505A(d)(4)(C)).
199. Id.
200. See id. § 355a(d)(4)(E) (FDCA § 505A(d)(4)(E)).
201. 42 U.S.C.S. § 290bo)(9)(B)(iii) (PHSA § 4990)(9)(B)(iii)).
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negotiating appropriate labeling changes with the holders of approved applications
for the drug studied.2 °2
C. Dispute Resolution for Labeling Changes
The new law creates a special dispute resolution procedure when FDA and
drug sponsors do not agree on appropriate pediatric labeling changes. These
dispute resolution procedures apply for labeling changes based on both studies
conducted by third parties under public contracts awarded by NIH, and based on
studies conducted by an NDA holder pursuant to a written request under section
505A of the FDCA. If there is no agreement on appropriate labeling changes
within 180 days after the submission of pediatric study reports, then the following
procedure is triggered:
" FDA refers the matter to the Pediatric Advisory Subcommittee of the Anti-
Infective Drugs Advisory Committee.
" Not later than 90 days after the referral, the Subcommittee makes a
recommendation to FDA as to appropriate labeling changes, if any.
" Within 30 days after receiving the recommendation, FDA makes a request
for labeling changes to all sponsors holding approved applications for the
drug, if appropriate.
" If a sponsor does not agree to make a requested labeling change within 30
days after receiving the request for the change from the agency, FDA "may
deem the drug to be misbranded. 2 3
The law states that nothing in these provisions limits the FDA's authority to
bring an enforcement action under the FDCA based on the lack of appropriate
pediatric labeling.2°
1. Additional Measures to Expedite Pediatric Labeling Changes
The law contains two additional provisions to expedite labeling changes
based on pediatric studies conducted under section 505A. First, the user fee waiver
that previously applied to pediatric supplements was eliminated, thereby providing
FDA with additional resources to review such applications. 20 Second, all pediatric
supplements submitted in accordance with section 505A will be considered
202. See id. § 290b(j)(9)(B)(iv) (PHSA § 499(j)(9)(B)(iv)).
203. 21 U.S.C.S. § 355a(i)(2) (LEXIS 1997 & Supp. 2002) (FDCA § 505A(i)(2)); 42 U.S.C.S.
§ 284m(c) (7)-(l 1) (Law Co-op 1994 & Supp. 2002) (PHSA § 4091(c)(7)-(1 1)). Misbranding is a
prohibited act under the FDCA and can lead to FDA enforcement action. See 21 U.S.C.S. § 331(b)
(FDCA § 301(b)).
204. 21 U.S.C.S. § 355a(i)(2)(E) (FDCA § 505A(i)(2)(E).
205. See id. § 379h(a)(1) (BPCA § 5(a)). Absent a waiver, a fee must be paid when a new drug
application or supplement is filed with FDA. See id. § 379h(a)(1) (FDCA § 736(a)(1)).
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"priority supplements" and will be subject to FDA's performance goals that apply
to priority drugs.2 °6
D. Additional Changes to Section 505A of the FDCA
1. The Pediatric List
The law amends section 505A of the FDCA to eliminate the so-called
"pediatric list. '20 7 Under the old law, a marketed drug had to be on the pediatric
list before FDA could issue a written request for pediatric studies. 2 8 Now, FDA
may issue written requests for pediatric studies of an already-marketed drug simply
if it determines that information relating to the use of the drug in the pediatric
population "may produce health benefits in that population. 20 9  This change
reflects FDA's prior implementation of section 505A. The pediatric list had played




The law amends section 505A to make clear that written requests may be
issued for studies in neonates, where appropriate.21'
3. Racial and Ethnic Minorities
The law requires that FDA take into account adequate representation of
children of ethnic and racial minorities when entering into written agreements
regarding protocols for studies under section 505A. 21
2
4. Dissemination of Pediatric Information
Under the new law, not later than 180 days after the submission of pediatric
reports in response to a written request under section 505A, FDA is required to
publish in the Federal Register a summary of FDA's medical and clinical
pharmacology reviews of the completed pediatric studies.21 3 This information will
be published whether or not the application or supplemental application with the
206. See id. § 321(kk) (FDCA § 201(kk)). The performance goals that apply to priority
supplements and certain other applications are those referred to in section 101(4) of the FDAMA, 111
Stat. 2298 (1997).
207. 115 Stat. at § 2.
208. 21 U.S.C. § 355a(b) (FDCA § 505A(b)); see also supra text accompanying note 63.
209. 21 U.S.C.S. § 355a(c) (LEXIS 1997 & Supp. 2002) (FDCA § 505A(c)); 115 Stat. at §2.
210. 21 U.S.C.S. § 355a(a), (c) (FDCA § 505A(a), (c)); see also supra text accompanying notes 64-
66.
211. 21 U.S.C.S. § 355a(a) (FDCA § 505A(a)); 115 Stat. at §4.
212. See 21 U.S.C.S. § 355a(d)(2) (FDCA § 505A(d)(2)); 115 Stat. at §18.
213. See 21 U.S.C.C. at § 355a(j) (FDCA § 505A(j) as amended by BCPA section 5(b)(2)); 115
Stat. at §9.
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new pediatric data has yet been approved. However, the law provides that it does
not alter or amend the public disclosure provisions of the FDCA, 14 the Freedom of
Information Act,215 or the Trade Secrets Act,216 which do not permit the disclosure
of trade secrets and confidential commercial information, among other things.21 7
E. Organizational Changes at FDA
1. Office of Pediatric Therapeutics
The law creates an Office of Pediatric Therapeutics within FDA. The Office
will be responsible for oversight and coordination of all agency activities that
involve or may have an effect on pediatric issues, and will coordinate with
employees of HHS who have responsibilities relating to pediatric therapeutics.
218
Office staff must include at least one additional individual with expertise in ethical
issues raised by the conduct of pediatric research, and at least one additional
219pediatric expert.
2. Pediatric Pharmacology Advisory Committee
The law establishes an FDA advisory committee on pediatric pharmacology
to advise and make recommendations on matters relating to pediatric
pharmacology, including the identification of research priorities and the need for
additional treatments for specific pediatric diseases or conditions. 220 The advisory
committee is to include representatives of pediatric health organizations, pediatric
researchers, patient and family organizations, and other experts.221
3. Pediatric Subcommittee of the Oncologic Drugs Advisory Committee The
law clarifies the mission of the Pediatric Subcommittee of the Oncologic Drugs
Advisory Committee (the Pediatric Oncology Subcommittee). The Pediatric
Oncology Subcommittee is specifically directed to evaluate and prioritize new and
emerging pediatric cancer treatments, provide guidance on timely patient access to
new therapies, and "advise on ways to improve consistency in the availability of
new therapeutic agents. 222 The Pediatric Oncology Subcommittee must request
participation of the following: at least two pediatric oncology specialists from the
National Cancer Institute; at least four pediatric oncology specialists from the
Children's Oncology Group, a pediatric oncology consortium sponsored by the
214. 21 U.S.C.S. § 331(j) (FDCA § 3016)).
215. Pub. L. No. 89-554, 80 Stat. 383 (1966) (codified as amended 5 U.S.C. §§ 552 et seq. (2000)).
216. 62 Stat. 791 (1948) (codified as amended 18 U.S.C. § 1905 (2000)).
217. 21 U.S.C.S. § 355a(m)(2) (LEXIS 1997 & Supp. 2002) (FDCA § 505A(m)(2)).
218. 115 Stat. at§ 6.
219. See id. § 6(c).
220. See id. § 14.
221. See id. § 14(c).
222. See id. § 15(a).
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National Cancer Institute (e.g., the Pediatric Brain Tumor Consortium), or
elsewhere with pediatric research expertise; at least two representatives of patients
or families; one representative of the nursing community; at least one statistician;
and at least one industry representative.223
F. Additional Provisions re: Pediatric Oncology
In addition to clarifying the mission of the Pediatric Subcommittee of the
Oncologic Drugs Advisory Committee, the law contains the following provisions
intended to spur research on pediatric cancer therapies:
* The law amends section 413 of the Public Health Service Act to direct the
National Cancer Institute to expand research on the development of
preclinical models for potential pediatric cancer therapies, and coordinate
such activities with those of other NIH research institutes and agencies.224
" The law amends the FDCA to require that applications to conduct new
clinical investigations (investigational new drug applications, or INDs)
include a statement of whether the sponsor has plans for assessing pediatric
safety and efficacy.
225
" The law amends section 4020) of the Public Health Service Act to require
that sponsors of studies required to be included in a clinical trial databank
previously established by FDAMA include a description for the databank of
whether and through what procedures the sponsor will respond to requests
to expand research protocols to allow broader use of a drug under study,
particularly for children.226 FDAMA previously required that NIH establish
a databank of information on clinical trials of drugs for serious or life-
threatening diseases and conditions.227
G. Adverse-Event Reporting
The law requires that FDA promulgate a final rule within one year, requiring
that the labeling of each drug approved under section 505 of the FDCA (regardless
of the date of approval) include the toll-free number maintained by FDA for
223. See id. § 15(a)(2)(B).
224. 42 U.S.C.S. § 285a-2 (Law Co-op 1994 & Supp. 2002).
225. 21 U.S.C.S. § 355(i)(1)(D) (LEXIS 1997 & Supp. 2002) (FDCA § 505(i)(1)(D)) (requiring the
submission to the Secretary by the manufacturer or the sponsor of the investigation of a new drug of a
statement of intent regarding whether the manufacturer or sponsor has plans for assessing pediatric
safety and efficacy).
226. 42 U.S.C.S. § 2820) (Law Co-op 1994 & Supp. 2002) (PHSA § 4020)).
227. See id.; see also Draft Guidance for Industry, Information Program on Clinical Trials for
Serious or Life-Threatening Diseases: Establishment of a Data Bank; Availability 65 Fed. Reg. 16,620
(March 29, 2000); see generally CTR. FOR DRUG EVALUATION & RES. (CDER) AND CTR. FOR
BIOLOGICS EVALUATION & RES. (CBER), FDA DRAFT GUIDANCE FOR INDUSTRY, INFORMATION
PROGRAM ON CLINICAL TRIALS FOR SERIOUS OR LIFE-THREATENING DISEASES: IMPLEMENTATION
PLAN (2001).
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adverse event reporting.228  The rule must be crafted in a manner that FDA
considers most likely to reach the broadest consumer audience, and must seek to
minimize the costs of the rule on the pharmacy profession.229
The law also requires that during the one-year period following a grant of
pediatric exclusivity, any adverse event report regarding the drug received by FDA
be referred to the new Office of Pediatric Therapeutics. 230 The Office of Pediatric
Therapeutics must provide for review of the report by the Pediatric Advisory
Subcommittee of the Anti-Infective Drugs Advisory Committee.23' Nothing in the
provision restricts FDA's authority to continue such procedures after the end of the
one-year period.232
H. Interaction with Other Exclusivity Periods
The BPCA clarified how pediatric exclusivity grants interact with certain
other available exclusivity periods. One such other type of exclusivity is available
to the first generic drug applicant to challenge the patents of an innovative drug
233sponsor. This is often referred to as "180 day exclusivity." The BPCA makes
clear that 180-day generic exclusivity periods do not start to run until an innovative
drug sponsor's pediatric exclusivity period has expired.234 This ensures that
generic drug sponsors entitled to 180-day exclusivity will not lose a portion of that
exclusivity due to the overlap with a pediatric exclusivity period.
The BPCA also addresses the interaction of pediatric exclusivity and the three
years of marketing exclusivity innovative drug sponsors can earn when they file
supplemental applications that contain new clinical investigations essential to
approval of the application.235 Drug sponsors who perform pediatric studies in
response to a written request under section 505A and who also obtain approval of
new pediatric labeling based on those studies are eligible to receive not only six
additional months of pediatric exclusivity for the drug as a whole, but also three
years of marketing exclusivity for the new pediatric labeling. That is, a generic
would not be able to include the new protected pediatric labeling for three years.
The BPCA provides that a generic drug shall not be considered ineligible for
approval or misbranded if the labeling for the generic drug omits a pediatric
228. 115 Stat. at § 17(a).
229. Id.
230. See id. § 17(b).
231. Id.
232. Id.
233. 21 U.S.C.S. § 355(j)(5)(B)(iv) (LEXIS 1997 & Supp. 2002) (FDCA § 505(j)(5)(B)(iv)); 115
Stat. at § 3; see also, Mova Pharm. Corp v. Shalala, 140 F.3d 1060, 1064-65 (D.C. Cir. 1998).
234. 21 U.S.C.S. § 355a(k) (FDCA § 505A(k)); 115 Stat. at § 10.
235. See 21 U.S.C.S. §§ 355(c)(3)(D)(iii); 3550j)(5)(D)(iii) (FDCA §§ 505(c)(3)(D)(iii);
505(j)(5)(D)(iii)); 115 Stat. at § 10; see also, Upjohn Co. v. Kessler, 938 F.Supp. 439, 441 (W.D. Mich.
1996) (explaining three-year market exclusivity provisions).
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indication or other aspect of labeling related to pediatric use that is protected by
patent or by three-year market exclusivity. 236 Where such labeling is omitted, FDA
may require that the labeling contain any necessary pediatric contraindications,
warnings, or precautions, as well as a statement that the generic is not labeled for
pediatric use because of marketing exclusivity for the pioneer." These provisions
do not otherwise affect pediatric exclusivity, market exclusivity for pediatric
formulations (as opposed to pediatric labeling), or the ability of generic drugs to
omit other labeling protected by exclusivity. 238 This provision of the law was
drafted in order to prevent a pioneer company from using three-year market
exclusivity for pediatric labeling to affect approval of a generic for adult
indications.239
I. Government Reports
1. Institute of Medicine Report on Protections for Research Subjects
The law directs the Secretary of HHS to contract with the Institute of
Medicine to review a variety of issues related to the protection of pediatric research
subjects and federal support for pediatric research. 240  Among the issues the
Institute of Medicine is to review are the process of obtaining informed consent
and assent, payments to children or parents for participating in research, the
monitoring of compliance with legal requirements, and the roles of institutional
review boards.24 ' A report of the Institute of Medicine will be submitted to
242Congress within 2 years. The report is to include recommendations on best
practices relating to research involving children.
243
2. Comptroller General Report on Pediatric Exclusivity Program
The law requires that the Comptroller General, in consultation with the
Secretary of HHS, submit a report to Congress by October 1, 2006 that addresses
(1) the effectiveness of the new law in ensuring that medicines are appropriately
tested and labeled for pediatric use, (2) the economic impact of the law (savings
from the more effective use of medicines, increased costs to consumers and the
government, increased sales for pioneer drugs), (3) the nature and type of studies
236. 21 U.S.C.S. § 355a(I) (FDCA § 505A(1)); 115 Stat. at § 11.
237. 21 U.S.C.S. § 355a(l)(2) (FDCA § 505A(1)(2)).
238. See id. § 355a(1)(3) (FDCA § 505A(1)(3)).
239. See H.R. REP. No. 107-277 at 30.
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conducted to earn pediatric exclusivity, (4) any recommendations for modifications
to the pediatric exclusivity program, (5) the increase in public and private research
capacity associated with the law, (6) the number of written requests and additional
letters of recommendation issued by FDA, (7) the prioritized list of off-patent
drugs for which FDA issues written requests, and (8) the efforts made by FDA to
increase the number of studies conducted in neonates (and the results of those
efforts). 24
3. General Accounting Office Report on Racial and Ethnic Minorities
The law also directs the General Accounting Office to conduct a study and
report to Congress by January 10, 2003 on (1) the extent to which children of
ethnic and racial minorities are adequately represented in pediatric studies
conducted under section 505A of the FDCA, (2) whether FDA has appropriate
systems to monitor the representation of children of ethnic and racial minorities in
such studies, and (3) whether drugs for diseases that disproportionately affect
racial and ethnic minorities are being studied under section 505A.245
4. FDA Report on Access to New Pediatric Cancer Therapies
By January 31, 2003, FDA, in consultation with NIH, must report to
Congress on patient access to new therapeutic agents for pediatric cancer,
including access to single patient use of new therapeutic agents.
246
5. FDA Implementation
Neither NIH nor FDA has yet implemented the primary provisions of the
BPCA. It is therefore not clear how the new public study programs for off-patent
and other drugs will operate in relation to the FDAMA exclusivity provisions or
the Pediatric Rule.
X. CONCLUSION
The available record demonstrates that the new pediatric initiative is working.
Drugs are being studied and labeled for use in different pediatric age groups, and
the capacity in the public and private sectors to perform pediatric research is vastly
expanded. This growth in the amount of pediatric research brings its own
challenges, including, in particular, a heightened imperative to ensure that the
rights of pediatric patients enrolled in studies are protected. There is no reason
why these additional challenges cannot be met and new research conducted within
appropriate legal and ethical bounds.
244. See id. § 16.
245. See id. § 17(b).
246. See id. § 15(d).
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There are, therefore, grounds for significant optimism at this point in the
evolving story of pediatric drug development. The federal government's efforts at
both the legislative and administrative levels over the past five years to expand
research on the use of medicines in pediatric patients have yielded unprecedented
results. The government has employed multi-pronged solutions to a complex
problem, using an innovative mixture of private market incentives, regulatory
mandates, and publicly funded research programs. Officials have shown a
willingness to try new approaches after prior attempts failed, and to continue to
refine even those programs that have worked, as reflected in the steps Congress
recently took when it reauthorized the pediatric exclusivity incentives while also
creating brand new pediatric programs at NIH. The challenge will be to maintain
that spirit of open-minded problem solving. As Dr. Shirkey's call echoes still in
our ears, if ever so slightly fainter, this is no time to stop the good work that has
begun.
